Obviously I like this review as they argue a similar case to mine, but without the mechanistic detail that I provide.
https://journals.physiology.org/doi/full/10.1152/ajpcell.00027.2026
Summary
This is a 2026 review by Khacho and Burelle on how mitochondria regulate muscle stem cells (MuSCs, or satellite cells). Its central argument is that mitochondria are not just ATP suppliers during muscle regeneration; they are state-control organelles that help decide whether a MuSC remains quiescent, activates, self-renews, commits to the myogenic lineage, differentiates, or becomes dysfunctional in disease.
The paper frames MuSC biology as a set of transitions:
| MuSC state | Mitochondrial/metabolic pattern | Functional meaning |
|---|---|---|
| Quiescence | Low metabolic rate, few mitochondria, low oxygen consumption, reliance on FAO/OXPHOS-like maintenance metabolism, low ROS, hypoacetylated chromatin | Preserves stemness and prevents inappropriate activation |
| Activation | Early glycolytic surge, rising mitochondrial membrane potential, ROS/redox signalling, transient mitochondrial fragmentation | Enables exit from quiescence, cell-cycle entry, biosynthesis and fate decisions |
| Proliferation/commitment | Increased mitochondrial activity, pyruvate use, TCA/OXPHOS upregulation, anabolic flux | Supports expansion and myogenic commitment |
| Differentiation | Mitochondrial biogenesis, cristae remodelling, OXPHOS maturation, fusion-dominant network | Supports mature myofiber energetics and contractile function |
A major theme is that mitochondrial metabolites influence the nucleus. The review highlights acetyl-CoA, NAD+/NADH, α-ketoglutarate, succinate, fumarate and SAM as bridges between mitochondrial metabolism and chromatin regulation. In quiescence, FAO and low glucose oxidation help maintain low histone acetylation; during activation, glucose-derived pyruvate and acetyl-CoA support histone acetylation and gene-expression remodelling.
The review also gives substantial attention to mitochondrial dynamics. Quiescent MuSCs have relatively elongated mitochondria, but activation involves DRP1-associated fission and reduced OPA1-mediated fusion. This fragmentation is linked to HGF/mTOR signalling, ROS/GSH signalling, and exit from quiescence. Later, differentiation requires ordered cycles of fission and fusion: early fission/mitophagy removes damaged mitochondria, followed by OPA1/MFN2-associated fusion, cristae remodelling and respiratory maturation.
A second key theme is mitophagy. The authors propose that quiescent MuSCs are “mitophagy-prone”: they maintain low-level mitochondrial clearance and hold a surprisingly large fraction of mitochondria in autophagolysosome-like compartments. PINK1/PARKIN appears most supported in quiescent MuSCs, while BNIP3-dependent mitophagy may be more important during differentiation. Activation appears to suppress mitophagy early, possibly to preserve the mitochondrial pool needed for proliferation.
The pathological sections argue that mitochondrial dysfunction is a recurrent feature of impaired muscle regeneration. In aging, MuSCs show defective mitochondrial dynamics, impaired OXPHOS, loss of membrane potential, mtDNA replication problems, reduced autophagy/mitophagy and increased stress signalling. The review notes that interventions such as DRP1 overexpression, dichloroacetate, rapamycin, urolithin A and nicotinamide riboside have been reported to improve aspects of aged MuSC function or regeneration.
In cancer cachexia and rhabdomyosarcoma, the review links defective myogenic differentiation to altered mitochondrial metabolism. Tumour-derived extracellular vesicles can reduce PGC1α signalling, oxygen consumption and differentiation capacity; rhabdomyosarcoma is presented as an extreme case of differentiation arrest linked to mitochondrial/metabolic dysfunction.
In sepsis, MuSCs show persistent regenerative impairment, reduced cycling and differentiation, mitochondrial loss, hyperpolarisation of remaining mitochondria, mtDNA damage and long-lasting OXPHOS pathway disruption. Mesenchymal stem cell therapy is described as restoring mitochondrial mass, membrane potential and mtDNA integrity, with improved regeneration.
In Duchenne muscular dystrophy, the review distinguishes mature-fiber mitochondrial dysfunction from emerging evidence that MuSCs and myoblasts themselves also have mitochondrial defects, including reduced respiratory capacity, increased ROS, altered membrane potential, impaired mitonuclear communication and reduced Pink1/Parkin expression. Urolithin A is discussed as a mitophagy-enhancing intervention that increased Pink1/Parkin expression and MuSC abundance in mdx muscle.
What is novel or useful about the paper
The novelty is mostly synthetic rather than experimental. This is a review, not a primary-data paper. Its value lies in integrating several previously separate areas:
-
It treats mitochondria as fate regulators, not just energy providers.
The review connects bioenergetics, redox signalling, metabolite-driven epigenetics, mitochondrial morphology and mitophagy into one framework for MuSC state transitions. -
It gives a state-by-state mitochondrial model of MuSC biology.
The paper’s figures are useful because they map quiescence, activation, commitment and differentiation onto changes in ATP demand, fuel use, ROS, mitochondrial morphology, mitophagy and chromatin regulation. The page 3 figure is especially helpful in showing the metabolic-epigenetic transition from quiescence to activation/differentiation. -
It emphasises mitophagy as state-specific.
Rather than saying “more mitophagy is good” or “less mitophagy is bad,” the paper proposes that quiescence, activation and differentiation require different mitophagy regimes: low-level quality control in quiescence, suppression during early activation, and a burst during differentiation. -
It links mitochondrial dynamics to fate decisions.
The review makes a strong case that fission/fusion balance is not merely a consequence of activation or differentiation. DRP1, OPA1 and MFN2 are presented as regulatory nodes controlling quiescence depth, commitment, mitochondrial quality control and myofiber maturation. -
It brings disease states into the same conceptual framework.
Aging, cachexia, sepsis and DMD are all discussed as conditions where MuSC regenerative decline may partly reflect mitochondrial state-control failure. -
It identifies clear research gaps.
The authors explicitly note that the field still relies heavily on transcriptomics to infer metabolism; direct metabolic flux, metabolomics, epigenomics and mechanistic mitochondrial-nuclear signalling studies are still limited.
Critique
The review is strong as a conceptual synthesis, but several caveats matter.
First, much of the model is based on indirect inference. The paper itself acknowledges that transcriptomic and proteomic data do not necessarily prove metabolic flux. For example, higher expression of FAO or OXPHOS genes in quiescent cells does not prove the actual carbon-flow rates through those pathways. This is important because quiescent MuSCs are technically difficult to study without activating them during isolation.
Second, the review sometimes moves from correlation to mechanism faster than the evidence fully permits. For instance, mitochondrial metabolites are plausibly linked to histone acetylation, DNA methylation and histone methylation, but the precise causal chains from mitochondrial state to specific MuSC gene programs remain underdefined. The authors acknowledge that mitochondrial-nuclear communication beyond ROS is still poorly mapped.
Third, the mitophagy model is interesting but still incomplete. PINK1/PARKIN is relatively well supported in quiescent MuSCs, while BNIP3 is suggested for differentiation, but several receptors such as NIX, FUNDC1, BCL2L13 and AMBRA1 are discussed with much weaker functional evidence. The review is appropriately cautious here, but the overall field still lacks clean receptor-specific loss-of-function studies across MuSC states.
Fourth, some disease sections necessarily rely on myoblasts, whole muscle or model systems, not freshly isolated quiescent MuSCs. This is especially relevant in DMD, cachexia and rhabdomyosarcoma. Mature myofiber mitochondrial dysfunction does not automatically imply the same mechanism operates in MuSCs.
Fifth, therapeutic implications are promising but not yet clinically settled. NR, urolithin A, rapamycin, DCA, PGC1α modulation, mitophagy enhancement and stem-cell-based mitochondrial rescue are plausible strategies, but the review does not establish which interventions are best, when they should be applied, or whether boosting mitochondrial activity could sometimes push MuSCs out of quiescence and deplete the stem-cell pool.
Sixth, the paper could have more sharply distinguished between quiescence maintenance and regenerative activation as therapeutic goals. In aging, one may want to preserve stemness before injury but promote activation and differentiation after injury. A therapy that improves one phase could impair another if mistimed.
Overall assessment
This is a useful and well-integrated review. Its main contribution is to place mitochondria at the centre of MuSC fate control through a combined model of metabolism, redox signalling, mitochondrial dynamics, mitophagy and epigenetic regulation.
The strongest parts are the state-transition framework and the discussion of DRP1/OPA1/MFN2 dynamics and mitophagy. The weaker parts are those that depend on inferred metabolic flux, incomplete mitophagy-receptor evidence, or extrapolation from myoblasts and whole-muscle disease models.
The key takeaway is: MuSC failure in aging and muscle-wasting disease may not simply reflect fewer stem cells or a bad niche; it may reflect loss of the correct mitochondrial state at the correct stage of regeneration.